http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107130021-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107130021-B |
| titleOfInvention | Application of CCAT1 long-chain non-coding RNA and small-molecule inhibitor thereof in hepatocellular carcinoma treatment |
| abstract | The invention discloses application of CCAT1 long-chain non-coding RNA and a small molecule inhibitor thereof in the aspect of hepatocellular carcinoma treatment. The invention discovers that the pyrrolopyrimidine ester I, the pyrrolopyrimidine ester II and the pyrrolopyrimidine ester III can obviously inhibit the expression of LncRNA CCAT1 in liver cancer Hep3b cells, thereby obviously inhibiting the in vitro proliferation and the in vivo tumor forming capability of the liver cancer Hep3b cells. The inhibitors of pyrrolopyrimidine ester I, pyrrolopyrimidine ester II, pyrrolopyrimidine ester III and other LncRNA CCAT1 can be used for developing and preparing medicaments for treating liver cancer. The invention has outstanding substantive features and obvious progress. |
| priorityDate | 2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 166.